FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics


You May Also Like

Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results

ALPHARETTA, Ga., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage ...

Immunomedics Appoints Michael R. Garone as New Chief Financial Officer

MORRIS PLAINS, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced ...